Remote Patient Monitoring Software Development

Remote patient monitoring software for one observation-to-clinician-review pathway.

We build a bounded RPM workflow around enrolment, device or patient observations, identity, consent, data quality, clinician-approved thresholds, review, acknowledgement, follow-up, EHR handoff, access, and audit. The client and its clinicians own device suitability, clinical interpretation, diagnosis, treatment, urgency, response, billing, safety, and regulatory decisions.

See our work

Bring the problem, the current workflow, or the existing code. We reply with a practical next step within one business day.

The brief

Start with what is not working.

Good software decisions begin with the constraint, not a list of features or a preferred technology.

01

Do readings reach a dashboard without enough identity, device, timing, quality, threshold, or care-plan context to support review?

02

Can the programme prove who saw an exception, what action they took, and what happened when a device, interface, or notification failed?

Plain answer

Remote patient monitoring software receives device or patient observations, validates identity and context, applies clinician-approved thresholds, and routes exceptions for review, acknowledgement, and follow-up. It does not diagnose or guarantee intervention. RaftLabs scopes one monitored pathway first, starting at $45K over 14 to 18 weeks.

What to remember

  • Remote patient monitoring software receives device or patient observations, validates identity and context, applies clinician-approved thresholds, and routes exceptions for review, acknowledgement, and follow-up, and it does not diagnose or guarantee intervention, with RaftLabs scoping one monitored pathway first.
  • A focused RPM release can include enrolment, device or patient observations, identity, consent, normalisation, data-quality state, clinician-approved threshold rules, review queues, acknowledgement, follow-up, role access, audit, an EHR handoff, and operations monitoring, while the clinical organisation defines the programme, response, records, and safety policy.
  • There is no diagnosis or treatment promise, since software surfaces readings and applies rules approved by the client, but clinicians own interpretation, diagnosis, treatment, urgency, escalation, and response, and any clinical decision support requires a defined intended use, appropriate evidence, oversight, risk controls, monitoring, and client-led regulatory review.
  • Device and EHR compatibility is confirmed during discovery against the specific device, vendor programme, SDK or API, data rights, market, and target EHR capability, and published work includes CGM and blood-pressure data, but that does not guarantee another model or interface, so one real data path should be proved before committing to broader coverage.
  • A first release starts at $45K and usually takes 14 to 18 weeks, covering one population and observation pathway, a proven device or entry route, approved rules, a clinician queue, acknowledgement, follow-up, role access, one integration, monitoring, and handover, while multiple devices, EHRs, markets, billing, or regulated decision support increase scope.

The reading arrived. The clinical task did not.

A device sent an out-of-range value, but the queue did not show whether it was current, duplicated, entered by the right patient, or already acknowledged. A notification left the system, yet nobody owned the failed delivery. Monitoring needs an accountable review path, not a stream of numbers.

Published RPM delivery

01
25+
clinics enrolled in 60 days
PDC remote patient monitoring case
02
4+
wearable device types supported
Published PDC delivery
03
14 weeks
platform delivery time
Published PDC first release

These are results from the published PDC remote patient monitoring case, not forecasts for a new programme. They do not prove clinical efficacy, diagnosis, treatment benefit, avoided visits, alert accuracy, billing acceptance, regulatory status, or safety. Another PDC phase reported 20% less clinical decision time after an AI layer was added; that is adjacent product evidence, not a guaranteed RPM outcome.

Build custom RPM software when the programme and clinical response already have accountable owners.

Use a supported RPM product when its devices, workflow, integrations, evidence, and service obligations fit.

A fit

A provider owns a distinct device or observation pathway, review model, escalation, records, and pilot that cannot be configured.

Clinical, device, privacy, security, accessibility, legal, billing, support, and product owners can approve evidence and release.

Representative readings, devices, users, gaps, duplicates, delays, outages, adverse cases, and interfaces are available for testing.

Not a fit

A maintained RPM platform already supports the devices, programme, EHR, assurance, operations, and service expectations.

The request assumes a reading, threshold, or model can diagnose, prescribe, assure response, or replace clinician judgement.

No staffed clinical review, escalation, device support, security, privacy, or live-service owner exists.

Choose the product by the event it owns

NeedBest fitPrimary boundary
Remote appointment or consultationTelehealth platformScheduling, identity, communication, consent, documentation, and encounter follow-up
Observation between encountersRemote patient monitoringDevice or patient data, quality, rules, clinical review, acknowledgement, and escalation
Patient access to messages, records, and tasksPatient portalIdentity, content, communication, forms, records, and service requests
Generic connected-device fleetIoT platformProvisioning, telemetry, device state, commands, maintenance, and operations without clinical interpretation

Scope

What belongs in one RPM pathway

  • 01

    Enrolment, identity, and consent

    Link the right patient, programme, device, clinician, consent version, care context, start and stop dates, accessibility needs, contact routes, and support ownership.
  • 02

    Observation and device data contract

    Preserve source, device identifier, measurement, units, timestamp, timezone, quality, provenance, sequence, duplicates, gaps, corrections, vendor state, and whether data is suitable for clinical review.
  • 03

    Clinician-approved rules and queues

    Apply approved thresholds and context, show why an item is surfaced, route it to a staffed role, record acknowledgement and disposition, expose overdue work, and keep a tested escalation and downtime path.
  • 04

    Clinical record and EHR handoff

    Connect observations, review state, notes, follow-up, and approved summaries to one target record. Preserve source identifiers, audit writes, retry safely, reconcile failures, and prevent the integration from silently becoming the authority.
  • 05

    Operations, privacy, and support

    Monitor ingestion, freshness, notification delivery, queues, access, exports, vendors, incidents, backups, recovery, and device support. The client and its advisers approve clinical, privacy, security, retention, billing, and regulatory policy.

How it works

From approved monitoring protocol to one accountable review pathway

  1. Phase 1
    01

    Define pathway, thresholds, and ownership

    Choose one population and observation path, devices, frequency, data-quality rules, clinician-approved thresholds, review hours, escalation, response, records, owners, risks, and acceptance measures.

  2. Phase 2
    02

    Prove devices, interfaces, and exceptions

    Test representative hardware or patient entry, identity, timestamps, units, duplicates, gaps, connectivity, vendor APIs, EHR capability, accessibility, notifications, downtime, and adverse cases.

  3. Phase 3
    03

    Build the bounded monitoring workflow

    Implement enrolment, device or observation ingestion, normalisation, approved rules, queues, acknowledgement, follow-up, role access, audit, one integration, monitoring, recovery, and support views.

  4. Phase 4
    04

    Pilot with clinicians and hand over

    Run normal, missing, delayed, duplicate, out-of-range, failed-delivery, outage, and escalation scenarios, reconcile records, review privacy and accessibility evidence, train owners, monitor, and release.

Risk

What the monitoring contract must settle

Clinical authority
The client and its clinicians define suitable patients and devices, thresholds, interpretation, urgency, review hours, response, escalation, documentation, and release.
Data quality
Wrong identity, units, timezones, duplicate transmissions, stale readings, missing data, device drift, and vendor outages must be visible and routed without presenting absence as normality.
Alert operations
A rule is not a response service. Staff queues, monitor delivery, record acknowledgement, measure load and delay, tune only under clinical approval, and rehearse downtime.
Compliance and device boundary
The client and qualified advisers own device classification, intended use, privacy, security, records, billing, contracts, regulatory obligations, and claims. Code alone cannot guarantee compliance or safety.

Scope and price

A focused remote patient monitoring pathway starts at $45K.

Start with one population, one proven device or observation route, approved rules, one clinical queue, one record handoff, and accountable operations.

Unlike general telehealth or IoT work, RPM must preserve clinical context and connect every surfaced observation to staffed review, acknowledgement, follow-up, and audit.

Starting investment

Starts at $45K

A focused release usually takes 14 to 18 weeks. Multiple devices, EHRs, markets, billing, AI, or regulated decision support increase scope.

No clinical guarantee

RaftLabs builds software; the client and its clinicians own interpretation, diagnosis, treatment, urgency, response, efficacy, safety, and regulatory decisions.

Exceptions are first-class

Missing, delayed, duplicate, stale, failed, unacknowledged, and outage scenarios belong in acceptance and live monitoring.

Proof

What clients say about working with RaftLabs

Three-year average engagement. Founders and operators describing the work in their own words. No marketing varnish.

I genuinely feel they care about where we're trying to take it.

Aaron McGoona

Founder, TicketStop

"All of the sprints were completed on schedule and on budget. We highly recommend RaftLabs!"

Charles E.

Entrepreneur at Aggie Technologies

Work with us

Bring the monitoring protocol, devices, clinical owner, and exception cases.

Share population, intended use, devices, observations, thresholds, review hours, response, escalation, records, EHR, connectivity, accessibility, privacy, pilot cohort, service levels, and owners.

  • Scope and cost agreed before work starts. No surprises. No obligation.
  • Working prototype within 3 weeks of kickoff.
  • Pay by milestone. You see progress before each invoice.
  • 60-day post-launch warranty. Bug fixes, UI tweaks, and deployment support. No retainer.
  • All conversations are NDA-protected.

Frequently asked questions

Straight answers to what buyers ask before they scope. Still stuck? .

A focused RPM release can include enrolment, device or patient observations, identity, consent, normalisation, data-quality state, clinician-approved threshold rules, review queues, acknowledgement, follow-up, role access, audit, an EHR handoff, and operations monitoring. The clinical organisation defines the programme, response, records, and safety policy.

No such promise is made. Software can surface readings and apply rules approved by the client, but clinicians own interpretation, diagnosis, treatment, urgency, escalation, and response. Any clinical decision support requires a defined intended use, appropriate evidence, oversight, risk controls, monitoring, and client-led regulatory review.

We confirm compatibility during discovery against the specific device, vendor programme, SDK or API, data rights, market, and target EHR capability. Published work includes CGM and blood-pressure data, but that does not guarantee another model or interface. We prove one real data path before committing to broader coverage.

Clinicians approve thresholds, context, severity, recipients, review hours, acknowledgement, escalation, and fallback. We test representative false positives, missing readings, duplicates, delayed data, notification failures, queue load, downtime, and handoff. Software helps prioritise work; the provider must staff, monitor, review, and improve the service.

A first release starts at $45K and usually takes 14 to 18 weeks. It covers one population and observation pathway, a proven device or entry route, approved rules, a clinician queue, acknowledgement, follow-up, role access, one integration, monitoring, and handover. A complete quote names the population and observation pathway in scope, the device or entry route being proved, who does what and who can see and change what, what 'done' looks like for the first pathway, the one record connection in scope, and anything left out. Multiple devices, EHRs, markets, billing, or regulated decision support increase scope, and any change is priced and approved in writing before the work is done.

You do, from day one. The code, the accounts, the patient and programme data, and the project notes are yours from the first day of the work, and the notes stay current as the build goes, so another team could pick the system up from them.

You already hold everything: the code, accounts in your name, your data, and current project notes, so a move is a handover of work in progress, not a release of anything we keep. We do not offer source-code escrow, because nothing is held back for escrow to release.

Penetration testing is taken care of before launch. No production data is used in development, always. Backups are tested, always. There are offboarding steps when someone leaves a team. Any third-party services the system depends on, such as device vendor programmes and the target EHR, are named in the scope document before signing. We claim practices we can show you, not certifications.

Where a programme runs in the United States, HIPAA is the regime that governs the patient data moving through a system like this one, and the duties under it stay with your organisation as the provider running the programme. They apply to this system because identified patient readings move through it. The build carries the software parts the scope names, such as who can see and change what, the audit trail, and how long records are kept. Compliance is shared, and no monitoring software makes an organisation compliant on its own. Because this work handles protected health information, we sign a Business Associate Agreement before we access any patient data.

Support after launch is its own written arrangement: an ongoing arrangement for threshold changes, new devices, and record-connection changes, a further fixed phase, or your own team running the system from the project notes and operations views. Software support is not clinical cover: the review queue stays staffed by your clinicians under your programme's response model. The costs that keep running are in your programme's own categories: device and vendor programme fees, EHR interface charges, hosting and monitoring, and the support arrangement itself.

A focused release usually takes 14 to 18 weeks across the page's four phases: defining the pathway, proving the devices and interfaces, building the bounded workflow, and piloting with clinicians. The calendar moves on ordinary things: how fast device vendor programme access and data rights are confirmed, when the target EHR's capability is proved, clinician time to approve thresholds and run the pilot scenarios, and pilot cohort readiness. The scope document is where the dates for your pathway are given in writing.

We work on five Remote Work Principles. 01 Switch to Async: the state of the build is readable without a meeting, which matters when your clinical team works set review hours. 02 Be Prepared: calls come with the pathway decisions and exception cases already laid out. 03 Write: thresholds, ownership, and decisions are written down, not left in call notes. 04 Ask and tell: a device or interface problem is said plainly and early, not at the deadline. 05 Own: the people on your project own their parts end to end.

Yes. We sign your NDA before anything sensitive is shared, and the scoping information you share, such as your monitoring protocol, device plans, and review model, stays confidential.

No. The people on your calls are the people on your project. Our team is based in India & Ireland, and the engineers who scope your pathway are the ones who build and pilot it with your clinicians. Nothing is handed off to another company.

We build with our own AI workflow process, RaftKit (raftkit.com). It runs in five phases, Blueprint, Plan, Build, Review, and Compound, with a quality gate at each phase and a two-stage review of the work, where the most serious problems block the work from going further. That is about how we write the software. It is separate from any AI layer inside your monitoring product, which stays a clinical decision for your organisation, with the evidence and oversight your programme requires.